HUNDREDS of people with lung cancer are expected to benefit from the UK National Institute for Health and Care Excellence (NICE) decision to recommended new drug osimertinib (Tagrisso from AstraZeneca).
Tagrisso has been registered in Australia since 03 Aug 2016.
For more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 16